Comparing anti-platelet therapy durations in kidney disease patients after stent placement

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the clinical outcomes of different durations of dual anti-platelet therapy, specifically aspirin combined with either clopidogrel or prasugrel, in patients with advanced chronic kidney disease who have undergone percutaneous coronary intervention using new generation drug eluting stents. It is a prospective, open-label, multicenter randomized trial that will compare the effects of at least 6 months of therapy against 3 months or less. The study seeks to determine the optimal duration of anti-platelet therapy to improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Over 19 years old
2. Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR \<45 / \<30 / \<15 or dialysis)
3. Patients treated with a new generation drug eluting stent.
4. Patients who signed consent form

Exclusion Criteria:

1. Over 85 years old
2. Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke, dementia or central nervous system damage within 1 year 3) Head trauma or brain surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6) Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8) In case of major surgery, trauma or bleeding within 3 weeks
3. Patients who need oral anticoagulant
4. Pregnant women or women of childbearing age
5. Life expectancy is less than 1 year
6. Patients with a history of intracranial bleeding
7. Moderate to severe hepatic impairment (Child-Pugh class B or C)

Where it's running

• Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Jung-Sun Kim, MD, PhD, FESC — Severance Hospital
• Study coordinator: Jung-Sun Kim, MD, PhD, FESC
• Email: KJS1218@yuhs.ac
• Phone: 82)-2)-2228-8457

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Impact of TAVR on kidney function in people with aortic valve disease

  This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07626710

• Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs

  This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.

  Recruiting Odense University Hospital · Odense · NCT07511283

• Oral Semaglutide for CKD and MAFLD in adults with diabetes

  This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07391267

• Eye-brain-kidney connections in chronic kidney disease

  This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.

  Recruiting Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07358572

• Screening for chronic kidney disease

  We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.

  Recruiting Institute for Clinical and Experimental Medicine · Prague · NCT07153432

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.